Neuraptive Therapeutics, Inc. Announces Appointment of Leading Industry Executive, Dr. Robert R. Ruffolo as New Director to the Board

View the full release here: https://www.businesswire.com/news/home/20221117005443/en/

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, November 17, 2022
Information
Tags: 
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, General Health, Health, Other Health, Ohio State University, GlaxoSmithKline, Therapy, Multimedia, Nerve injury, Physician, Development, Nerve, Eli Lilly and Company, Patient, Pharmaceutical industry, Pharmacology, Pfizer, Pharmacy, Research
Geotags: 
PENNSYLVANIA, UNITED STATES, NORTH AMERICA, OHIO, PHILADELPHIA
⚠ partially generated by AI ↴
Summary
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221117005443/en/
    On behalf of the Neuraptive Board and its directors, we are excited to welcome Bob to the board, said Robert Radie, chairman, and chief executive officer of Neuraptive.
  • His extensive experience in drug research and development is a great addition to the Neuraptive board at this important time.
  • Dr. Ruffolo is the retired President of Research and Development of Wyeth Pharmaceuticals, and Corporate Senior Vice President of the Wyeth Corporation (now Pfizer).
  • Prior to Wyeth, Dr. Ruffolo held executive roles at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Lilly Research Laboratories.


Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by nerve injuries, announced the appointment of industry R&D pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D. to the company’s Board of Directors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005443/en/

Robert R. Ruffolo, Ph.D. (Photo: Business Wire)

Robert R. Ruffolo, Ph.D. (Photo: Business Wire)

“On behalf of the Neuraptive Board and its directors, we are excited to welcome Bob to the board,” said Robert Radie, chairman, and chief executive officer of Neuraptive. “His extensive experience in drug research and development is a great addition to the Neuraptive board at this important time. We are fortunate to have attracted such an accomplished leader in our industry which speaks to the promise and potential of the work we are doing to transform the treatment of peripheral nerve injuries."

Dr. Ruffolo has over 40 years of research and development experience and is currently the Chairman of Aragen Biosciences, Inc. and Managing Director of Ruffolo Consulting, LLC, a consulting company for the pharmaceutical and biotechnology industries. Dr. Ruffolo is the retired President of Research and Development of Wyeth Pharmaceuticals, and Corporate Senior Vice President of the Wyeth Corporation (now Pfizer). He managed an R&D organization of 9,000 scientists with an annual budget in excess of $5 billion. Prior to Wyeth, Dr. Ruffolo held executive roles at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Lilly Research Laboratories. He earned his Ph.D. in Pharmacology and his B.S. in Pharmacy from The Ohio State University.

About Neuraptive

Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia, PA. For more information, see www.neuraptive.com.

Copyright: 
Copyright Business Wire 2022